Lantern Pharma Schedules Type C Meeting with the FDA to Advance HARMONIC™ Protocol Amendments Targeting This High-Need Population, Reflecting LP-300’s Novel Mechanism of Action and the Rapidly ...
Exon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS; Durable Responses Beyond Two Years; and a Consistently Clean Safety Profile. "Our LP-300 program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results